ResMed Inc. (RMD)
NYSE: RMD · Real-Time Price · USD
256.55
+5.04 (2.00%)
Dec 5, 2025, 4:00 PM EST - Market closed
ResMed Stock Forecast
Stock Price Forecast
According to 11 professional analysts, the 12-month price target for ResMed stock ranges from a low of $269 to a high of $330. The average analyst price target of $292.27 forecasts a 13.92% increase in the stock price over the next year.
Price Target: $292.27 (+13.92%)
Analyst Consensus: Buy
* Price targets were last updated on Nov 3, 2025.
Analyst Ratings
The average analyst rating for ResMed stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 2 | 2 | 2 |
| Buy | 6 | 6 | 6 | 6 | 7 | 7 |
| Hold | 3 | 3 | 3 | 4 | 4 | 4 |
| Sell | 1 | 1 | 1 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 13 | 13 | 12 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Baird | Baird | Buy Maintains $320 → $300 | Buy | Maintains | $320 → $300 | +16.94% | Nov 3, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $300 → $303 | Buy | Maintains | $300 → $303 | +18.11% | Oct 31, 2025 |
| Keybanc | Keybanc | Buy Maintains $298 → $299 | Buy | Maintains | $298 → $299 | +16.55% | Oct 31, 2025 |
| Mizuho | Mizuho | Buy Maintains $310 → $300 | Buy | Maintains | $310 → $300 | +16.94% | Oct 31, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $298 → $304 | Buy | Maintains | $298 → $304 | +18.50% | Oct 21, 2025 |
Financial Forecast
Revenue This Year
5.65B
from 5.15B
Increased by 9.81%
Revenue Next Year
6.06B
from 5.65B
Increased by 7.31%
EPS This Year
10.97
from 9.51
Increased by 15.38%
EPS Next Year
12.10
from 10.97
Increased by 10.28%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 6.0B | 6.5B | |||
| Avg | 5.7B | 6.1B | |||
| Low | 5.4B | 5.8B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 15.6% | 14.5% | |||
| Avg | 9.8% | 7.3% | |||
| Low | 5.3% | 2.5% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 11.71 | 13.21 | |||
| Avg | 10.97 | 12.10 | |||
| Low | 10.14 | 11.40 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 23.1% | 20.4% | |||
| Avg | 15.4% | 10.3% | |||
| Low | 6.7% | 3.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.